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Abstract
Background: The role of human papillomavirus (HPV) as single or multiple infections
in pregnant women would be relevant to determine the time to progression and/or the
time to regression of cervical lesions.
Objective: In this preliminary study, we determined the prevalence of HPV as single or
multiple infections in pregnant women from Northeastern Mexico.
Materials and Methods: Samples from 31 pregnant and 62 nonpregnant women were
examined between January 2015 and November 2015 at UMAE-23 of the Instituto
Mexicano del Seguro Social (IMSS). The samples of cervicovaginal exudate were
obtained for HPV DNA detection using the INNO-LiPA test, and HPV infections were
analyzed as single or multiple infections. Participants completed a questionnaire on
sociodemographic, gynecological, obstetric, and sexual behavior characteristics.
Results: The mean age of the pregnant women was 25.7 ± 4.8 yr, with an average
time of pregnancy of 6 ± 1 months at the time of the study. With respect to age,
parity, smoking history, or oral contraceptive use no statistically significant differences
between the two studied groupswas observed. TheHPV infectionwas 2.7 times higher
in pregnant women (35%) than in the control group (13%). In total, 78% of the pregnant
women who were HPV-positive presented with single infections compared with 28%
of the nonpregnant women.
Conclusion: A higher prevalence of HPV as a single infection was found in this sample
of pregnant Mexican women. Follow-up is necessary to evaluate the persistence or
regression of the infection.
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1. Introduction
In Mexico, cervical carcinoma is the second
most common neoplasia and the second most
frequent cause of death by cancer in women
(1). Human papillomavirus (HPV) types 16, 18, 31,
45, and 58 are the most frequent in cervical
samples from Mexican patients (2). Many factors
can increase the risk of HPV infection; for example,
sexual behavior, number of sexual partners,
vaginal infection, and early onset of sexual activity.
Diet, smoking, genetic factors, and immune
suppression are also related to HPV infection
(3-6). Studies have reported that pregnancy
affects the immune system of the host and alters
seroreactivity to HPV infection (7, 8). Another
important factor that should be considered in
HPV-infected patients is the genotype distribution
between single and multiple infections. Recently,
Aguilar- Lemarroy and co-workers reported a
higher prevalence of the HPV genotype as a
single infection in Mexican patients with cervical
cancer (2). Few studies have addressed the
role of HPV as single or multiple infections in
pregnant women. However, this information
would be relevant to determining the time to
progression and/or the time to regression of
cervical lesions.
Thus, this case-control study was conducted
to investigate the presence of HPV as single
or multiple infections in cervical samples from
pregnant and nonpregnant women using the
INNO-LiPA test.
2. Materials and Methods
2.1. Subjects and sample collection
Thirty-one pregnant women between age
19 and 27 years in the third trimester of
pregnancy and 62 non-pregnant women (as
controls) within a similar age range (18-28 yr)
were prospectively enrolled in this cross-
sectional study from January 2015 to November
2015.
All pregnant women who visited the Gynecology
and Obstetrics Department of UMAE-23, Instituto
Mexicano del Seguro Social (IMSS), Mexico, for
the first time during pregnancy were invited
to join the study. A gynecologist explained
the aim of the study, the procedures, and
the complications involved. Control samples
were obtained from women attending early
cancer detection programs at the same
hospital. This was followed by an interview
conducted by research assistants, in which all
the participants responded to a questionnaire
respecting reproductive history and sexual
behavior.
None of the women included in the study
presented cervical lesions, as assessed by
clinical examination of the cervix, cytology,
and colposcopy. Women with immunosuppressive
diseases, as hepatitis C, hepatitis B, HIV, and
diabetes mellitus, were eliminated from the
study.
Cervical samples were obtained with a
cytobrush in the course of gynecological
exploration. The cytobrush was inserted into
the endocervical canal, rotated 3 to 5 times,
placed into the transport medium (Preserv-Cyt
solution; Hologic, Bedford, MA), and immediately
sent to the Laboratory of Molecular Cytogenetics
of Centro de Investigación Biomédica del Noreste,
IMSS, Mexico. Cervical scraping samples were
frozen at -20°C until DNA extraction. DNA
was extracted using a Wizard Genomic DNA
Purification Kit (Promega, Madison, WI). The
DNA quantity and quality were verified using a
NanoDrop® Jenway kit (Genova Life Science, OSA,
UK).
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2.2. Detection/genotyping
The INNO-LiPA HPV genotyping test
(Innogenetics N.V., Ghent, Belgium) directs the
amplification of a 65 bp region of the HPV L1
gene and allows the identification of 28 anogenital
HPV genotypes: twelve high-risk (HR) HPVs, one
probable HR HPV, seven possible HR HPVs, and
eight low-risk HPVs (9). Two internal controls and
two positive controls (both 65 bp products from
the HPV L1 region) were included. Results from
specimens where the controls failed to amplify
were excluded from the study. The INNO-LiPA test
permits the simultaneous detection of multiple
genotypes in a single sample.
2.3. Ethical consideration
Written informed consent was obtained from
all participants and the study protocol was
reviewed and approved by the Ethics and Scientific
Committee of IMSS (Code: 293539).
2.4. Statistical analysis
The risk of HPV infection associated with
pregnancy [odds ratio (OR) and 95% confidence
interval (CI)] was estimated by logistic regression,
P < 0.05 using the IBM SPSS Statistics, version 22
(SPSS, Inc., Chicago, IL).
3. Results
No statistically significant differences were
found between the two groups regarding age,
(age mean, 25.7 ± 4.8 years in for pregnant
women vs 28.6 ± 5.1 years in nonpregnant), parity,
smoking during pregnancy, oral contraceptive
use, and history of sexually transmitted infections
(Table I).
Among the 31 pregnant women studied here,
11 (35%) were HPV-positive. Of these, eight (73%)
were infected with a single genotype and three
(27%) were infected with multiple genotypes. HPV-
16 was detected in six pregnant women (54%; five
as a single infection and one as multiple infections).
Among the 62 nonpregnant women, eight were
HPV-positive (12%). Of these, three (36%) were
infected with a single genotype and five (64%) were
infected with multiple genotypes. The HPV-44 and
HPV-52 genotypes were the most prevalent in all
cases involving multiple infections (Table II).
A multivariate analysis showed that pregnancy
was associated with an increased risk for multiple
HPV infection (OR, 2.75; 95% CI, 1.15-6.59) and for
single HPV infection (OR, 4.6667; 95% CI, 1.0814-
20.1388).
Table I. Clinical characteristics of the pregnant and non-pregnant women
Non-pregnancy Pregnancy
Number of studied women 62 31
Age (yr) (X ± SD) 28.6 ± 5.1 25.7 ± 4.8
Parity (X ± SD) 1.9 ± 2.4 2.3 ± 2.1
Current smokers *(%) 23 29
Oral contraceptive +(%) 18 24
Sexually transmitted infections (%) 11 9
X ± SD = Mean ± standard deviation, *Current smokers were defined as women who had smoked at least 100 cigarettes in
their lifetime and were smoking at the time of the visit, +Women who had used oral contraceptives for more than one year
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Table II. HPV genotype distribution (single and multiple) in pregnant and non-pregnant women








Sub-total 8 (72.7) 3 (37.5)
Multiple
6, 11, 39 1 -
6, 11, 58 1 -
11, 16, 31, 33, 44, 51, 52 1 -
16, 26, 31, 33, 44, 51, 52, 54, 69-71, 82 - 1
44, 52, 58 - 1
51, 82 - 1
44, 52, 58, 69-71 - 1
16, 31, 33, 44, 52, 54 - 1
Sub-total 3 (27.3) 5 (62.5)
TOTAL 11 (100) 8 (100)
HPV-low risk: 6, 11, 44, 54; HPV-high risk: 16, 18, 31, 33, 35, 39, 51, 52, 58, and 8.2; HPV-possible high risk: 26, 69-71
For HPV infection (OR, 2.75; 95% CI, 1.15-6.59), For single HPV infection (OR, 4.6667; 95% CI, 1.0814-20.1388)
4. Discussion
In this preliminary study, we determined the
prevalence of HPV as single or multiple infections
in pregnant women from Northeastern Mexico.
Our findings revealed a significant increase in
HPV prevalence among pregnant women (35%)
compared with nonpregnant women (13%) (OR =
2.7).
Studies comparing the distribution of HPV
types in pregnant and nonpregnant women are
scarce in the Mexican population. Hernández-
Girón et al. (10, 11) reported a higher prevalence of
HR HPV infection in pregnant women compared
with nonpregnant women, with detection rates
of 37.2% (95% CI, 31-43) and 14.2% (95% CI, 12-
16), respectively. Previous studies have reported
similar findings (12-14).
Liu et al. (15) performed a meta-analysis of
the risk of HPV infection in pregnant women
from Asia, Europe, and North America and found
a significantly increased risk among pregnant
women (16%, 13%, and 30%, respectively), with a
general OR of 1.42.
In contrast, Nobbenhuis (16) found no difference
in HPV prevalence between pregnant and
nonpregnant women. Such discrepancies
may have arisen from the HPV detection
method used and the number of detectable
HPV genotypes. In our study, we used the
INNO-LiPA test, which is able to identify 28
anogenital HPV genotypes and includes two
internal controls and two positive controls.
The INNO-LiPA test permits the simultaneous
detection of multiple genotypes in a single
sample.
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Previous study reported a dependence of HPV
prevalence on age (11), parity, smoking history,
oral contraceptive use, and history of sexually
transmitted infections. In our study, the groups
under study were homogeneous in terms of these
factors (17-19).
A possible explanation for the higher
prevalence of HPV found in pregnant women
respect to nonpregnant women is based that
immunosuppression occurs during pregnancy
because of the reduction of cellular immunity
(7). It has been suggested that the high levels
of estrogen and progesterone that occur during
pregnancy decrease the cellular immunity, which is
crucial for resolve the HPV infection. Our previous
results showed that a high prevalence of HPV-52
and HPV-44 was involved in multiple infections
in nonpregnant women (2). In contrast, a high
prevalence of HPV-16 as a single infection was
observed in pregnant women.
Interestingly, our results revealed that 78% of
the pregnant women who were HPV-positive
presented with a single infection compared with
28% of the nonpregnant women.
The transcriptional promoter of the E6/E7
oncogenic region of HPV-16 contains a steroid-
hormone-receptor-binding element that activate
HPV E6/E7 transcription, suggesting a hormonal
stimulation effect on HPV replication. These
observations indicate that pregnancy may have
an effect on the patient’s capacity to eradicate
multiple HPV infections (20). Yamasaki (21)
reported that accelerated clearance of HPV
may be caused by the normalization of the host’s
immune system during the third trimester of
pregnancy. Thus, the presence of HR HPV in the
late period of pregnancy can be considered as
being persistent and, therefore, represents a risk
factor for neoplastic lesions.
In conclusion, a higher prevalence of HPV as
a single infection in pregnant women was found,
despite the number of women included in the
study was relatively small. Further investigations
are necessary to establish the biological role of
HPV as a single infection and its participation in the
development of precancerous lesions or cervical
carcinoma.
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